<DOC>
	<DOCNO>NCT01675102</DOCNO>
	<brief_summary>17p-/p53-mutated chronic lymphocytic leukemia ( CLL ) orphan disease , account approximately 5 % newly diagnose CLL . This subgroup patient poor outcome chemoimmunotherapy . Allogeneic HCT may change poor prognosis . In retrospective EBMT-analysis 44 patient advanced 17p-CLL 2-year progression-free survival 45 % ( 95 % CI , 30 % 60 % ) allogeneic HCT ( Allogeneic hematopoietic stem-cell transplantation chronic lymphocytic leukemia 17p deletion : retrospective European Group Blood Marrow Transplantation analysis . J Clin Oncol , 2008 , 26 , 5094-5100 ) . Referring favorable result small additional series , patient 17p-CLL require therapy consider indication allogeneic transplantation many CLL study group . Several CLL study group recommend allogeneic HCT 17p-CLL part first- second line treatment . The aim collect additional evidence allogeneic HCT 17p-/p53-mutated CLL first second remission non-interventional prospective study . Patients shall register prior HCT Leiden Office order rule report bias transplantation .</brief_summary>
	<brief_title>Allogeneic Hematopoietic Stem Cell Transplantation ( HSCT ) 17p- Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>Objective : The aim determine early PFS allogeneic HCT first second remission 17p-/p53-mutated CLL within epidemiologic study . Methods : Neither decision allogeneic transplantation specific treatment recommendation patient 17p-/p53-mutated CLL part study . Instead , study protocol refers EBMT guideline . Indications allogeneic stem cell transplantation chronic lymphocytic leukemia : EBMT transplant consensus . Leukemia 21 , 2007 , 12-17 ) . Minimal essential data ( MED ) A B , define EBMT , collect ( www.ebmt.org ) . The rate progression-free survival ( PFS ) 1 year HSCT select primary endpoint . Death , clinical relapse progression immune manipulation ( taper immunosuppression , DLI , rituximab ) consider treatment failure PFS . Patients without information one-year follow consider experienced treatment failure . The rate PFS 1 year calculate dividing number patient without treatment failure number patient meet selection criterion . For calculation sample size fixed sample design select . The null hypothesis success-rate PFS equal less 50 % . Referring retrospective EBMT survey , PFS one year allogeneic HCT expect 70 % . According Fleming-A'Hern ( 1982 ) null hypothesis reject power 80 % alpha error 5 % minimum 24 37 informative patient experience treatment failure first year allogeneic HCT ( Machin et al , Sample Size Tables Clinical Studies , Wiley-Blackwell , 3rd edition , 2009 ) . Taking account 10 % drop-out rate violation inclusion criterion target number patient include set 41 patient .</detailed_description>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>17p/p53mutated CLL FISH sequencing , confirm review experience laboratory first second partial remission complete remission HCT accord update NCIcriteria ( Hallek 2008 ) MRD diagnostic part local standard follow allogeneic HCT match related unrelated donor one mismatch refer HLAA , B , C DRB1 ex vivo Tcell depletion vivo Tcell depletion alemtuzumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>del 17p</keyword>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>cll</keyword>
	<keyword>mutation</keyword>
	<keyword>p53</keyword>
</DOC>